http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002003403-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88dd137bc7573765384d60e2e1156e69 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2001-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a1bc7e337c8b848762160c3347555c5 |
| publicationDate | 2002-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2002003403-A |
| titleOfInvention | Cancer treatment |
| abstract | (57) [Summary] [Objective] To provide a new means of immunological cancer treatment. [Constitution] NK involved in activation of NKT cells responsible for cancer immunity T cells have two different antigen receptors, namely NK R-P1 (natural killer P1) and Vα24Vβ11 The present invention was completed by finding out that the actions of NKR-P were completely different, and NKR-P A therapeutic agent for cancer, which uses an effect on 1 (natural killer P1) as an index. |
| priorityDate | 2001-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 140.